

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD.
Balance Sheet

As at 31st Mar	Notes No	2014 USD	2014 INR (' In Thousands)	2013 USD	2013 INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital	1	1	0		
Reserves & surplus	2	7,083,530	424,374	-	-
		7,083,531	424,374	-	-
Current liabilities					
Trade payables	3	3,993	239	-	-
		3,993	239	-	-
Total		7,087,524	424,614	-	-
II. ASSETS					
Non-current investments					
	4	7,087,523	424,614	-	-
		7,087,523	424,614	-	-
Current assets					
Short-term loans and advances	5	1	0		
		1	0		
Total		7,087,524	424,614	-	-

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD.
Statement of Profit and Loss

For the year ended 31st March,	Notes No	2014	2014	2013	2013
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES					
Other expenses	6	3,993	247	-	-
Total expenses		3,993	247	-	-
Profit for the Year		(3,993)	(247)	-	-

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

Drug Discovery and Development Solutions Limited, Singapore

CASH FLOW STATEMENT

For the year ended 31st March,	2014	2014
	USD	INR (' In Thousands)
A. Cash flows from operating activities		
Net income before minority interest	(3,993)	(247)
Operating profit before working capital changes	(3,993)	(247)
Adjustments for :		
(Increase)/Decrease in trade and other receivables	(1)	(0)
Increase/(Decrease) in trade and other payables	3,993	241
	(1)	(5)
Net cash inflow/(outflow) in course of operating activities	(1)	(5)
B. Cash flow arising from financing activities :		
Proceeds from issue of share capital(including share premium & net of share issue expenses)	1	0
Net cash inflow/(outflow) in course of financing activities	1	0
C. Foreign currency translation difference arising on consolidation		5
Net Increase in cash & cash equivalents (A+B+C)	-	-
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	-	-

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

Rajneesh Gupta

Head Accounts

Place : Noida

Date : 22nd May, 2014

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD.

Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
Equity Share Capital	-	-	-	-
Preference share capital	-	-	-	-
Issued & Subscribed				
1 equity shares of USD 1 each	-	-	-	-
Paid up				
1 equity shares of USD 1 each	1	0	-	-
	1	0	-	-

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential

3) The details of shareholders holding more than 5% shares in the company :

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No of shares	% held	No of shares	% held
Jubilant Life Sciences Ltd, India -Holding company	1	100%	-	0%

4) The reconciliations of number of shares outstanding at beginning and at the end of reporting period

As at 31st Mar	2014	2014	2013	2013
	No	INR (' In Thousands)		INR (' In Thousands)
Numbers of shares at the beginning	-	-	-	-
Add: Shares issued during the year	1	0	-	-
Numbers of shares at the end	1	0	-	-

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No	INR (' In Thousands)		INR (' In Thousands)
Jubilant Life Sciences Ltd, India-Holding company				
1 equity shares of USD 1 each	1	0	-	-

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD.

Notes to the Financial Statements

As at 31st Mar	2014 USD	2014 INR (' In Thousands)	2013 USD	2013 INR (' In Thousands)
2. RESERVES AND SURPLUS				
Capital Reserve				
As per last Balance Sheet				
Additions/Consequent of acquisition	7,087,523	437,655	-	-
	7,087,523	437,655	-	-
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve During the Year	-	(13,034)	-	-
	-	(13,034)	-	-
Surplus as per P&L Account				
As per last Balance Sheet				
Add: Net Profit after tax transferred from Statement of Profit and Loss	(3,993)	(247)	-	-
	(3,993)	(247)	-	-
	7,083,530	424,374	-	-
3. TRADE PAYABLES				
Trade payables-others	3,993	239	-	-
	3,993	239	-	-
4. NON-CURRENT INVESTMENTS				
Investment in Subsidiary/ Fellow subsidiaries Companies				
JUBILANT LIFE SCIENCES (BVI) LTD				
3,972,501 equity shares of USD 1 each	3,952,898	236,818		
JUBILANT INNOVATION (BVI) LTD				
16,255,000 equity shares of USD 1 each	3,134,625	187,795		
	7,087,523	424,614	-	-
5. SHORT TERM LOANS AND ADVANCES				
- Advance recoverable in cash & kind				
- From related parties	1	0	-	-
	1	0	-	-
6. OTHER EXPENSE				
Legal , professional & consultancy charges	3,993	247	-	-
	3,993	247	-	-